153 related articles for article (PubMed ID: 38268648)
1. Early Dynamic Risk Stratification Decreases Rate of Ablative and Adjuvant Radioiodine Use in ATA Low and Intermediate Risk Papillary Thyroid Cancer Patients.
Gorur SK; Ozbas S; Ilgan S
Sisli Etfal Hastan Tip Bul; 2023; 57(4):451-457. PubMed ID: 38268648
[TBL] [Abstract][Full Text] [Related]
2. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
[TBL] [Abstract][Full Text] [Related]
3. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
4. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
5. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
[TBL] [Abstract][Full Text] [Related]
6. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
7. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
8. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi.
Kukulska A; Krajewska J; Gawkowska-Suwińska M; Puch Z; Paliczka-Cieslik E; Roskosz J; Handkiewicz-Junak D; Jarzab M; Gubała E; Jarzab B
Thyroid Res; 2010 Nov; 3(1):9. PubMed ID: 21040579
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.
Satapathy S; Tupalli A; Chandekar KR; Ballal S; Bal C
Clin Endocrinol (Oxf); 2023 Nov; 99(5):483-491. PubMed ID: 37491776
[TBL] [Abstract][Full Text] [Related]
13. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
14. Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma.
Signore A; Lauri C; Di Paolo A; Stati V; Santolamazza G; Capriotti G; Prosperi D; Tofani A; Valabrega S; Campagna G
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296937
[TBL] [Abstract][Full Text] [Related]
15. Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma.
Cadena-Piñeros E; Escobar JV; Carreño JA; Rojas JG
World J Nucl Med; 2022 Dec; 21(4):290-295. PubMed ID: 36398303
[No Abstract] [Full Text] [Related]
16. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
James DL; Ryan ÉJ; Davey MG; Quinn AJ; Heath DP; Garry SJ; Boland MR; Young O; Lowery AJ; Kerin MJ
JAMA Otolaryngol Head Neck Surg; 2021 Jun; 147(6):544-552. PubMed ID: 33792650
[TBL] [Abstract][Full Text] [Related]
17. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
18. Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer - a prospective comparison of long-term outcomes.
Kukulska A; Krajewska J; Gawkowska M; Paliczka-Cieslik E; Handkiewicz-Junak D; Kropińska A; Puch Z; Olczyk T; Roskosz J; Jarzab B
Arch Med Sci; 2022; 18(5):1241-1247. PubMed ID: 36160333
[TBL] [Abstract][Full Text] [Related]
19. Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?
Han K; Noh HM; Jeong HM; Lim YC
Ann Surg Oncol; 2021 Nov; 28(12):7533-7544. PubMed ID: 34043093
[TBL] [Abstract][Full Text] [Related]
20. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
